Immunic (IMUX) News Today → This is the best new way to score with AI (From Weiss Ratings) (Ad) Free IMUX Stock Alerts $1.30 +0.01 (+0.78%) (As of 05/15/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13 at 4:48 AM | americanbankingnews.comQ4 2024 Earnings Forecast for Immunic, Inc. Issued By Leerink Partnrs (NASDAQ:IMUX)May 10, 2024 | markets.businessinsider.comHold Rating on Immunic Amidst Ongoing Vido Clinical Trials and Financial OutlookMay 9, 2024 | finance.yahoo.comImmunic, Inc. (NASDAQ:IMUX) Q1 2024 Earnings Call TranscriptMay 9, 2024 | finance.yahoo.comWe Think Immunic (NASDAQ:IMUX) Needs To Drive Business Growth CarefullyMay 8, 2024 | msn.comIMUX Stock Earnings: Immunic Misses EPS for Q1 2024May 8, 2024 | proactiveinvestors.comImmunic advances ‘potentially groundbreaking' MS therapy vidofludimus calcium during Q1May 8, 2024 | prnewswire.comImmunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 7, 2024 | msn.comImmunic Q1 2024 Earnings PreviewMay 6, 2024 | prnewswire.comImmunic to Participate in Investor and Scientific Conferences in MayMay 3, 2024 | benzinga.comImmunic Stock (NASDAQ:IMUX), Quotes and News SummaryMay 2, 2024 | marketbeat.comImmunic (IMUX) to Release Earnings on WednesdayImmunic (NASDAQ:IMUX) will be releasing earnings before the market opens on Wednesday, May 8, Zacks reports.May 1, 2024 | prnewswire.comImmunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate UpdateApril 30, 2024 | proactiveinvestors.comImmunic publishes extended data from Phase 2 MS trial in peer-reviewed journalApril 30, 2024 | prnewswire.comImmunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & NeuroinflammationApril 29, 2024 | finance.yahoo.comImmunic CEO Dr Daniel Vitt marks International Day of Immunology with discussion on its crucial roleApril 19, 2024 | marketbeat.comImmunic (NASDAQ:IMUX) Upgraded by StockNews.com to "Hold"StockNews.com upgraded Immunic from a "sell" rating to a "hold" rating in a report on Friday.April 19, 2024 | finance.yahoo.comImmunic, Inc. (IMUX)April 16, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP) and Immunic (IMUX)April 15, 2024 | marketbeat.comShort Interest in Immunic, Inc. (NASDAQ:IMUX) Rises By 22.7%Immunic, Inc. (NASDAQ:IMUX - Get Free Report) was the recipient of a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 3,030,000 shares, an increase of 22.7% from the March 15th total of 2,470,000 shares. Based on an average daily volume of 976,400 shares, the days-to-cover ratio is presently 3.1 days.April 12, 2024 | morningstar.comImmunic Inc IMUXApril 5, 2024 | msn.comBrookline Capital starts Immunic at buy, cites MS drug candidateApril 5, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Immunic (IMUX) and Shockwave Medical (SWAV)April 5, 2024 | marketbeat.comImmunic (NASDAQ:IMUX) Research Coverage Started at Brookline Capital ManagementBrookline Capital Management started coverage on Immunic in a research note on Friday. They issued a "buy" rating and a $10.00 target price for the company.April 4, 2024 | finance.yahoo.comWith 44% ownership, Immunic, Inc. (NASDAQ:IMUX) has piqued the interest of hedge funds investorsApril 4, 2024 | finance.yahoo.comImmunic to Host MS R&D Day and Participate in Investor Conferences in AprilApril 1, 2024 | marketbeat.comShort Interest in Immunic, Inc. (NASDAQ:IMUX) Expands By 11.3%Immunic, Inc. (NASDAQ:IMUX - Get Free Report) was the target of a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 2,470,000 shares, an increase of 11.3% from the February 29th total of 2,220,000 shares. Based on an average daily trading volume, of 977,100 shares, the short-interest ratio is currently 2.5 days.March 29, 2024 | marketbeat.comImmunic (NASDAQ:IMUX) Downgraded to "Sell" at StockNews.comStockNews.com lowered shares of Immunic from a "hold" rating to a "sell" rating in a report on Friday.March 20, 2024 | marketwatch.comImmunic Gets Allowance for Vidofludimus Calcium Patent ApplicationMarch 20, 2024 | proactiveinvestors.comImmunic granted patent for specific polymorph of vidofludimus calcium in USMarch 20, 2024 | prnewswire.comImmunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United StatesMarch 18, 2024 | marketbeat.comShort Interest in Immunic, Inc. (NASDAQ:IMUX) Declines By 11.9%Immunic, Inc. (NASDAQ:IMUX - Get Free Report) was the recipient of a significant drop in short interest in the month of February. As of February 29th, there was short interest totalling 2,220,000 shares, a drop of 11.9% from the February 14th total of 2,520,000 shares. Based on an average daily volume of 943,800 shares, the short-interest ratio is presently 2.4 days.March 18, 2024 | proactiveinvestors.comImmunic CMO discusses complexities of multiple sclerosis to mark MS Awareness MonthMarch 11, 2024 | marketbeat.comImmunic (NASDAQ:IMUX) Upgraded to Hold at StockNews.comStockNews.com raised Immunic from a "sell" rating to a "hold" rating in a research note on Monday.March 7, 2024 | prnewswire.comImmunic to Participate in Investor and Scientific Conferences in MarchFebruary 29, 2024 | proactiveinvestors.comImmunic to present data for lead asset vidofludimus calcium from Phase 2 MS and COVID-19 trialsFebruary 29, 2024 | prnewswire.comImmunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024February 26, 2024 | markets.businessinsider.comHold Rating on Immunic: Balancing Long-Term Potential Against Short-Term UncertaintiesFebruary 23, 2024 | finance.yahoo.comImmunic Inc (IMUX) Reports Year-End 2023 Financial ResultsFebruary 23, 2024 | finance.yahoo.comImmunic, Inc. (NASDAQ:IMUX) Q4 2023 Earnings Call TranscriptFebruary 22, 2024 | markets.businessinsider.comBuy Rating Affirmed for Immunic Amid Progress in IMU-838 Trials and Extended Financial RunwayFebruary 22, 2024 | proactiveinvestors.comImmunic expects financial stability through 2025 as MS clinical programs advanceFebruary 22, 2024 | proactiveinvestors.comImmunic reports successful 2023 and prepares for key 2025 milestonesFebruary 22, 2024 | finance.yahoo.comImmunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate UpdateFebruary 22, 2024 | prnewswire.comImmunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate UpdateFebruary 21, 2024 | benzinga.comImmunic Stock (NASDAQ:IMUX) Dividends: History, Yield and DatesFebruary 21, 2024 | benzinga.comImmunic's Earnings OutlookFebruary 16, 2024 | marketbeat.comImmunic (IMUX) to Release Earnings on ThursdayImmunic (NASDAQ:IMUX) will be releasing earnings before the market opens on Thursday, February 22, Zacks reports.February 15, 2024 | proactiveinvestors.comImmunic's cutting-edge MS treatment approach: insights from CEO Dr Daniel VittFebruary 15, 2024 | finance.yahoo.comImmunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate UpdateFebruary 15, 2024 | prnewswire.comImmunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update Get Immunic News Delivered to You Automatically Sign up to receive the latest news and ratings for IMUX and its competitors with MarketBeat's FREE daily newsletter. Email Address The most important AI company you've never heard of (Ad)Because this small company solves the BIGGEST problem with Nvidia's AI chips. Already, Amazon, Microsoft, Google and others are lining up to get this company's products. Get the full story on this secret AI company poised for massive growth IMUX Media Mentions By Week IMUX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMUX News Sentiment▼0.520.55▲Average Medical News Sentiment IMUX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMUX Articles This Week▼102▲IMUX Articles Average Week Get Immunic News Delivered to You Automatically Sign up to receive the latest news and ratings for IMUX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Cartesian Therapeutics News Abeona Therapeutics News Vistagen Therapeutics News Coya Therapeutics News Karyopharm Therapeutics News Cellectar Biosciences News Nuvectis Pharma News OptiNose News Societal CDMO News Rezolute News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMUX) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersHow to Play the AI and Crypto Markets in One SwingWeiss RatingsAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
